XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings (Tables)

Long-Term Debt and Other Financings (Tables)

3 Months Ended

Mar. 31, 2020

Aggregate Future Principal, Final Payment Fees and Discounts of Long-Term Debt

Aggregate future principal, final payment fees and discounts of the Company’s long-term debt as of March 31, 2020, are as follows (in thousands):


2020 (excluding three months ended March 31, 2020)	$	4,868
2021		8,534
2022		21,798
Thereafter		—
Total payments		35,200
Less: interest, final payment fees, discount and issuance costs		(3,669)
Total payments, net of interest, final payment fees, discount and issuance costs		31,531
Less: current portion of long-term debt		(6,390)
Long-term debt	$	25,141

Interest Expense and Amortization of Debt Issuance Costs and Discounts

Amortization of debt issuance costs and discounts are included in interest expense. Interest expense in the condensed consolidated statements of operations and comprehensive (loss) income relates to the following debt instruments (in thousands):


	Three Months Ended March 31,
	2020		2019
SVB loan	$	383	$	242
Novartis note		158		186
Other		1		1
Total interest expense	$	542	$	429